Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Pharmabiz23h
Septerna discontinues phase 1 clinical trial of SEP-786; plans to advance next-generation oral small molecule PTH1R agonist
Septerna discontinues phase 1 clinical trial of SEP-786; plans to advance next-generation oral small molecule PTH1R agonist: South San Francisco, California Friday, February 21, 2 ...